MetaCap

Edesa Biotech Inc. (EDSA)

NASDAQ: EDSAHealth CareBiotechnology: Pharmaceutical PreparationsUSD

2.00-0.175 (-8.05%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

EDSA stock chart

Technical analysis

Key statistics

All statistics
Market cap
$27.02M
EPS (TTM)
-$1.72
52-week range
0.72 – 20.32
Day range
1.97 – 2.18
Volume / Avg
120.96K / 1.45M
Beta
—
Next earnings
Dec 11, 2026

52-week range

$0.72$20.32

EDSA stock today

On Nov 20, EDSA ended the session at $2.00, shedding $0.175 (8.05%), versus the S&P 500's 3.70% decline. Trading was light, with 120.96K shares changing hands, about 8% of the average daily volume. Shares are 90.2% below their 52-week high of $20.32, set on May 1, 2026 and 177.8% above the 52-week low of $0.72, near the bottom of the past year's range.

EDSA is up 40.8% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 17.6%. Edesa Biotech has posted a net loss over the last twelve months (EPS of -$1.72), so its P/E ratio is not meaningful. The company is scheduled to report Sep/2026 results on Dec 11; analysts expect EPS of -$0.57.

Summary generated from market data by MetaCap's automated system. Methodology

About Edesa Biotech

Company profile

Edesa Biotech, Inc., a clinical-stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products for inflammatory and immune-related diseases. It develops EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome; and EB01, a topical vanishing cream containing non-steroidal anti-inflammatory compound that has completed Phase 3 clinical study to treat chronic allergic contact dermatitis. The company develops EB07, a monoclonal antibody, which is in a Phase 2 clinical study for the treatment of pulmonary fibrosis; and EB06, a human monoclonal antibody candidate that binds to chemokine ligand 10 (CXCL10) and inhibits the interaction of CXCL10 with its receptors, CXCR3A, and CXCR3B.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Dr. Pardeep Nijhawan FRCPC, M.D.
Headquarters
Markham, ON
Employees
17

Financial highlights

Full financials

Edesa Biotech reported a net loss of $7.2 million, compared with a loss of $6.2 million a year earlier.

Edesa Biotech annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue———$780.00K$0
Growth————-100.00%
Net income$-7.19M$-6.17M$-8.37M$-17.55M$-13.34M
EPS (diluted)————$-1.10

Analyst forecast

Forecast

Consensus (2 analysts)

none

Avg. price target

$16.33+716.50%

  • Strong buy 0
  • Buy 2
  • Hold 0
  • Sell 0
  • Strong sell 0

Target range

Low $9.00High $21.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Next report
Dec 11, 2026
EPS estimate
$-0.57
Last reported (Q3 2026)
Aug 13, 2026
EPS actual vs est.
$-0.60 vs —

EDSA news

All EDSA news

Edesa Biotech peers

Health Care sector
EDSA peer companies
CompanyPrice% ChgMarket capCompare
NSRXNasus Pharma Ltd.2.29-10.20%$26.82Mvs EDSA
TELOTelomir Pharmaceuticals Inc.0.364-17.24%$26.82Mvs EDSA
BCTXBriaCell Therapeutics Corp.3.06-3.32%$26.72Mvs EDSA
PMNProMIS Neurosciences Inc.3.16-1.56%$28.43Mvs EDSA
AYTUAytu BioPharma Inc.2.660.00%$28.91Mvs EDSA
ATHEAlterity Therapeutics Limited ADR1.52-8.16%$29.02Mvs EDSA
RNTXRein Therapeutics Inc.0.3369-8.38%$29.06Mvs EDSA
NNVCNanoViricides Inc.1.14-2.56%$29.13Mvs EDSA

Indexes, lists and sector

Edesa Biotech stock FAQ

What is Edesa Biotech's stock price today?

EDSA last traded at $2.00 as of Nov 20, 4:00 PM EST, down 8.05% on the day. Prices are delayed at least 15 minutes.

Does Edesa Biotech pay a dividend?

No. Edesa Biotech does not currently pay a regular cash dividend.

When is Edesa Biotech's next earnings date?

Edesa Biotech is expected to report earnings on Friday, December 11, 2026. Analysts expect EPS of $-0.57.

Who is Edesa Biotech's CEO?

Dr. Pardeep Nijhawan FRCPC, M.D. is the chief executive officer of Edesa Biotech Inc., which has about 17 employees.

Has EDSA ever split its stock?

Yes. The most recent EDSA stock split was a 1-for-7 split on Oct 11, 2023, one of 4 splits on record.

What is the EDSA 52-week high?

The 52-week high for EDSA is $20.32 and the 52-week low is $0.72. The stock is currently 90.2% below its high.

Compare EDSA